HomeCompareCADNF vs ABBV

CADNF vs ABBV: Dividend Comparison 2026

CADNF yields 4.12% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CADNF wins by $332.1K in total portfolio value· pulled ahead in Year 4
10 years
CADNF
CADNF
● Live price
4.12%
Share price
$8.39
Annual div
$0.35
5Y div CAGR
49.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$434.4K
Annual income
$236,237.74
Full CADNF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CADNF vs ABBV

📍 CADNF pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCADNFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CADNF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CADNF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CADNF
Annual income on $10K today (after 15% tax)
$350.27/yr
After 10yr DRIP, annual income (after tax)
$200,802.08/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CADNF beats the other by $179,746.07/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CADNF + ABBV for your $10,000?

CADNF: 50%ABBV: 50%
100% ABBV50/50100% CADNF
Portfolio after 10yr
$268.4K
Annual income
$130,504.75/yr
Blended yield
48.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CADNF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
1.8
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CADNF buys
0
ABBV buys
0
No recent congressional trades found for CADNF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCADNFABBV
Forward yield4.12%3.06%
Annual dividend / share$0.35$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR49.8%40.6%
Portfolio after 10y$434.4K$102.3K
Annual income after 10y$236,237.74$24,771.77
Total dividends collected$392.0K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: CADNF vs ABBV ($10,000, DRIP)

YearCADNF PortfolioCADNF Income/yrABBV PortfolioABBV Income/yrGap
1$11,317$617.30$11,550$430.00$233.00ABBV
2$13,088$978.07$13,472$627.96$384.00ABBV
3$15,587$1,583.49$15,906$926.08$319.00ABBV
4← crossover$19,319$2,640.29$19,071$1,382.55+$248.00CADNF
5$25,252$4,581.29$23,302$2,095.81+$1.9KCADNF
6$35,404$8,383.76$29,150$3,237.93+$6.3KCADNF
7$54,338$16,455.65$37,536$5,121.41+$16.8KCADNF
8$93,500$35,358.63$50,079$8,338.38+$43.4KCADNF
9$185,224$85,179.35$69,753$14,065.80+$115.5KCADNF
10$434,428$236,237.74$102,337$24,771.77+$332.1KCADNF

CADNF vs ABBV: Complete Analysis 2026

CADNFStock

Cascades Inc. produces, converts, and markets packaging and tissue products in Canada and the United States. The company operates through three segments: Containerboard, Specialty Products, and Tissue Papers. It manufactures containerboards, as well as converts corrugated products. The company also offers uncoated recycled paperboards for use in packaging converters and industrial users of headers and wrappers for the paper industry, as well as partitions that are used as protective packaging; honeycomb paperboards for the beer, wine, and spirits industry; laminated paperboards for food packaging and furniture backing industries; and specialty containers, structural components, and paperboard and fiber composites. In addition, it provides egg filler flats and egg cartons for egg processors and four-cup carriers for the quick-service restaurant industry; polystyrene foam trays for processors and retailers in the food industry; rigid plastic packaging products for food industry, processors, and retailers; and flexible films for frozen foods, bakery, and ice industries. Further, the company offers bathroom and facial tissues, paper towels, paper hand towels and napkins, and other related products and services under the Cascades PRO Signature, Cascades PRO Perform, Cascades PRO Select, Cascades PRO Tandem, and Cascades PRO Tuff-Job brands; and under the Cascades Fluff, Cascades Tuff, and Satin Soft labels, as well as private labels and other secondary marks. Additionally, it offers services to recover and process discarded materials for the municipal, industrial, commercial, and institutional sectors. The company sells its products through own sales force and external representatives. Cascades Inc. was incorporated in 1964 and is headquartered in Kingsey Falls, Canada.

Full CADNF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CADNF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CADNF vs SCHDCADNF vs JEPICADNF vs OCADNF vs KOCADNF vs MAINCADNF vs JNJCADNF vs MRKCADNF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.